RxDoctor Payments Data

Sonia Sharma, MD

Family Medicine · Crown Point, INNPI 1669737664

Payments from drug & device makers

$1,892in general payments, 2019–2025

Across 103 payments — averaging $18.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$327
  • Lilly USA, LLC$291
  • Novo Nordisk$241
  • Currax Pharmaceuticals LLC$193
  • AbbVie$169
  • Pfizer$161
  • plus $510 from 15 others

What the payments were for

  • Food & beverage$1,86799%
  • Education$251%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,892 in reported general payments places this provider in the 70th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$21,676
Medicare patients
48
Services billed
251

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide116$136,788
MounjaroTirzepatide14$27,693
VascepaIcosapent Ethyl14$5,129
Ventolin HfaAlbuterol Sulfate11$797
Pregabalin12$602
Naltrexone Hcl12$476
Albuterol Sulfate HfaAlbuterol Sulfate34$466
Omeprazole16$267
Venlafaxine Hcl ErVenlafaxine Hcl15$257
Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide23$251
Bupropion XlBupropion Hcl26$233
Losartan Potassium29$200
Amlodipine Besylate46$198
Lisinopril46$184
Levothyroxine Sodium20$173

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$241$136,788116 claims
Lilly USA, LLCMounjaro$291$27,69314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Crown Point

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →